Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Improving Metabolism With HDL Cholesterol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00395148
Recruitment Status : Completed
First Posted : November 2, 2006
Last Update Posted : May 10, 2011
Baker Heart Research Institute
Information provided by:
Bayside Health

Brief Summary:
High levels of good cholesterol (HDL) in our blood decreases our chance of having a heart attack. This relates in part to the role good cholesterol plays in reducing build up of fat in the arteries. However, good cholesterol has many other protective effects. We have recently identified three enzymes (proteins) activated by HDL in cells lining the blood vessels, which may be responsible for some of HDL's protective actions.

Condition or disease Intervention/treatment Phase
Heart Disease Diabetes Drug: rHDL Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol
Study Start Date : March 2006
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Metabolic parameters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18 - 65 years
  • Free of overt coronary disease
  • Body mass index <35 kg.m-2
  • Fasting plasma glucose > 7 mmol/L-1
  • No major illness

Exclusion Criteria:

  • Unable to give informed consent
  • Smokers
  • Abnormal LFT, U&E, FBE or creatinine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00395148

Layout table for location information
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Bayside Health
Baker Heart Research Institute
Layout table for investigator information
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
Publications of Results:

Layout table for additonal information
Responsible Party: Prof Bronwyn Kingwell, Baker IDI Heart & Diabetes Institute Identifier: NCT00395148    
Other Study ID Numbers: 175/04
First Posted: November 2, 2006    Key Record Dates
Last Update Posted: May 10, 2011
Last Verified: October 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiovascular Diseases